1. Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer
- Author
-
Dominik Pfister, Moritz Peiseler, Roland Rad, Monika Julia Wolf, Suchira Gallage, Elena Kotsiliti, Caroline L. Wilson, Tjeerd P. Sijmonsma, Nabil Djouder, Marco Prinz, Daniela C. Kroy, Frank Tacke, Jerry Ware, Adnan Ali, Roser Pinyol, Mike Notohamiprodjo, Tracy O'Connor, Christopher J. Weston, Paul Kubes, Bas G.J. Surewaard, Percy A. Knolle, Achim Weber, Michael D. Milsom, Patrick M. Helbling, Daniel Dauch, Tobias Geisler, Mohsen Malehmir, Carsten Deppermann, Alexander Olkus, Marcel Rall, Hellmut G. Augustin, Lars Zender, Julia Volz, Ana Teijeiro, César Nombela-Arrieta, Malte N. Bongers, Valentina Leone, Mathias Heikenwalder, Matthias S. Matter, Dominic J. Withers, Lozan Sheriff, Alexandros Vegiopoulos, Oliver Krenkel, Oliver Borst, Patricia F. Lalor, Jack Leslie, Anahita Rafiei, Florian Baku, David H. Adams, Adam J. Rose, Bernhard Nieswandt, Thomas Engleitner, Hannah K. Drescher, Dominik Rath, Natasha S Anstee, Marlene Kohlhepp, Marc E. Healy, Marta Szydlowska, Meinrad Gawaz, Ruzhica Bogeska, Kristian Unger, Donato Inverso, David Stegner, Martina Hinterleitner, Derek A. Mann, Josep M. Llovet, Medical Research Council, and Wellcome Trust
- Subjects
0301 basic medicine ,Platelet Aggregation ,NF-KAPPA-B ,Research & Experimental Medicine ,0302 clinical medicine ,Non-alcoholic Fatty Liver Disease ,HEPATOCELLULAR-CARCINOMA ,Platelet ,Hyaluronic Acid ,11 Medical and Health Sciences ,Liver Neoplasms ,Fatty liver ,Platelet Glycoprotein GPIb-IX Complex ,MOUSE MODEL ,General Medicine ,3. Good health ,Hyaluronan Receptors ,Medicine, Research & Experimental ,Liver ,030220 oncology & carcinogenesis ,Cytokines ,Platelet aggregation inhibitor ,GLYCOPROTEIN-VI ,Liver cancer ,Life Sciences & Biomedicine ,Blood Platelets ,Biochemistry & Molecular Biology ,Kupffer Cells ,FACTOR BINDING ,Immunology ,Mice, Transgenic ,Cytoplasmic Granules ,digestive system ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,INFLAMMATION ,medicine ,Animals ,Humans ,Endothelium ,Platelet activation ,Science & Technology ,IN-VIVO DEPLETION ,ANTIPLATELET THERAPY ,Platelet Count ,business.industry ,SET ENRICHMENT ANALYSIS ,Body Weight ,Cell Biology ,medicine.disease ,digestive system diseases ,030104 developmental biology ,Hepatocytes ,Cancer research ,Steatohepatitis ,Steatosis ,business ,Platelet Aggregation Inhibitors ,CAUSES NONALCOHOLIC STEATOHEPATITIS - Abstract
Non-alcoholic fatty liver disease ranges from steatosis to non-alcoholic steatohepatitis (NASH), potentially progressing to cirrhosis and hepatocellular carcinoma (HCC). Here, we show that platelet number, platelet activation and platelet aggregation are increased in NASH but not in steatosis or insulin resistance. Antiplatelet therapy (APT; aspirin/clopidogrel, ticagrelor) but not nonsteroidal anti-inflammatory drug (NSAID) treatment with sulindac prevented NASH and subsequent HCC development. Intravital microscopy showed that liver colonization by platelets depended primarily on Kupffer cells at early and late stages of NASH, involving hyaluronan-CD44 binding. APT reduced intrahepatic platelet accumulation and the frequency of platelet-immune cell interaction, thereby limiting hepatic immune cell trafficking. Consequently, intrahepatic cytokine and chemokine release, macrovesicular steatosis and liver damage were attenuated. Platelet cargo, platelet adhesion and platelet activation but not platelet aggregation were identified as pivotal for NASH and subsequent hepatocarcinogenesis. In particular, platelet-derived GPIbα proved critical for development of NASH and subsequent HCC, independent of its reported cognate ligands vWF, P-selectin or Mac-1, offering a potential target against NASH.
- Published
- 2019
- Full Text
- View/download PDF